Try a new search

Format these results:

Searched for:

in-biosketch:yes

person:morgag04

Total Results:

677


The current landscape of multiple myeloma treatment

Cavo, Michele; Attal, Michel; Gertz, Morie A; Giralt, Sergio; Ludwig, Heinz; Morgan, Gareth J; Anderson, Kenneth C
PMID: 18954677
ISSN: 0145-2126
CID: 3650272

Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936

van Krieken, J H J M; Langerak, A W; Macintyre, E A; Kneba, M; Hodges, E; Sanz, R Garcia; Morgan, G J; Parreira, A; Molina, T J; Cabeçadas, J; Gaulard, P; Jasani, B; Garcia, J F; Ott, M; Hannsmann, M L; Berger, F; Hummel, M; Davi, F; Brüggemann, M; Lavender, F L; Schuuring, E; Evans, P A S; White, H; Salles, G; Groenen, P J T A; Gameiro, P; Pott, Ch; Dongen, J J M van
The diagnosis of malignant lymphoma is a recognized difficult area in histopathology. Therefore, detection of clonality in a suspected lymphoproliferation is a valuable diagnostic criterion. We have developed primer sets for the detection of rearrangements in the B- and T-cell receptor genes as reliable tools for clonality assessment in lymphoproliferations suspected for lymphoma. In this issue of Leukemia, the participants of the BIOMED-2 Concerted Action CT98-3936 report on the validation of the newly developed clonality assays in various disease entities. Clonality was detected in 99% of all B-cell malignancies and in 94% of all T-cell malignancies, whereas the great majority of reactive lesions showed polyclonality. The combined BIOMED-2 results are summarized in a guideline, which can now be implemented in routine lymphoma diagnostics. The use of this standardized approach in patients with a suspect lymphoproliferation will result in improved diagnosis of malignant lymphoma.
PMID: 17170732
ISSN: 0887-6924
CID: 3706642

Haplotype uncertainty in association studies

Mensah, F K; Gilthorpe, M S; Davies, C F; Keen, L J; Adamson, P J; Roman, E; Morgan, G J; Bidwell, J L; Law, G R
Inferring haplotypes from genotype data is commonly undertaken in population genetic association studies. Within such studies the importance of accounting for uncertainty in the inference of haplotypes is well recognised. We investigate the effectiveness of correcting for uncertainty using simple methods based on the output provided by the PHASE haplotype inference methodology. In case-control analyses investigating non-Hodgkin lymphoma and haplotypes associated with immune regulation we find little effect of making adjustment for uncertainty in inferred haplotypes. Using simulation we introduce a higher degree of haplotype uncertainty than was present in our study data. The simulation represents two genetic loci, physically close on a chromosome, forming haplotypes. Considering a range of allele frequencies, degrees of linkage between the loci, and frequency of missing genotype data, we detail the characteristics of genetic regions which may be susceptible to the influence of haplotype uncertainty. Within our evaluation we find that bias is avoided by considering haplotype probabilities or using multiple imputation, provided that for each of these methods haplotypes are inferred separately for case and control populations; furthermore using multiple imputation provides the facility to incorporate haplotype uncertainty in the estimation of confidence intervals. We discuss the implications of our findings within the context of the complexity of haplotype inference for larger marker rich regions as would typically be encountered in genetic analyses.
PMID: 17323369
ISSN: 0741-0395
CID: 3706662

Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936

Evans, P A S; Pott, Ch; Groenen, P J T A; Salles, G; Davi, F; Berger, F; Garcia, J F; van Krieken, J H J M; Pals, S; Kluin, Ph; Schuuring, E; Spaargaren, M; Boone, E; González, D; Martinez, B; Villuendas, R; Gameiro, P; Diss, T C; Mills, K; Morgan, G J; Carter, G I; Milner, B J; Pearson, D; Hummel, M; Jung, W; Ott, M; Canioni, D; Beldjord, K; Bastard, C; Delfau-Larue, M H; van Dongen, J J M; Molina, T J; Cabeçadas, J
Polymerase chain reaction (PCR) assessment of clonal immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements is an important diagnostic tool in mature B-cell neoplasms. However, lack of standardized PCR protocols resulting in a high level of false negativity has hampered comparability of data in previous clonality studies. In order to address these problems, 22 European laboratories investigated the Ig/TCR rearrangement patterns as well as t(14;18) and t(11;14) translocations of 369 B-cell malignancies belonging to five WHO-defined entities using the standardized BIOMED-2 multiplex PCR tubes accompanied by international pathology panel review. B-cell clonality was detected by combined use of the IGH and IGK multiplex PCR assays in all 260 definitive cases of B-cell chronic lymphocytic leukemia (n=56), mantle cell lymphoma (n=54), marginal zone lymphoma (n=41) and follicular lymphoma (n=109). Two of 109 cases of diffuse large B-cell lymphoma showed no detectable clonal marker. The use of these techniques to assign cell lineage should be treated with caution as additional clonal TCR gene rearrangements were frequently detected in all disease categories. Our study indicates that the BIOMED-2 multiplex PCR assays provide a powerful strategy for clonality assessment in B-cell malignancies resulting in high Ig clonality detection rates particularly when IGH and IGK strategies are combined.
PMID: 17170731
ISSN: 0887-6924
CID: 3706632

Collection of peripheral blood stem cells in new patients with myeloma receiving minimal or no prior cytoreductive therapy

Sirohi, Bhawna; Powles, Ray; Cavanagh, Jamie; Oakervee, Heather; Dyer, P; Rintala, T; Kulkarni, Samar; Rudin, Claudius; Horton, Clive; Treleaven, Jennifer; Morgan, Gareth
The aim of the study was to evaluate whether adequate stem cells (CD34+) could be harvested at presentation in myeloma patients such that high dose melphalan (HDM) with autologous stem cell rescue can be offered as primary therapy. The regimes either involved no prior cytoreductive chemotherapy (steroids only, n = 31) or a single course of VAD (n = 22). The median number of CD34 cells collected with steroids was 1.3 x 10(6) (0.2-5.6) compared to 4.6 x 10(6) (0.3-19.2) cells/kg with VAD (P < 0.0001). We conclude that it is possible to collect stem cells from myeloma patients at presentation with minimal prior therapy. Using this strategy, of a single prior course of chemotherapy followed by immediate harvest, it is feasible to offer early high-dose therapy in clinical situations where this is important.
PMID: 17454191
ISSN: 1607-8454
CID: 3695812

A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma [Letter]

de Tute, R M; Jack, A S; Child, J A; Morgan, G J; Owen, R G; Rawstron, A C
PMID: 17657223
ISSN: 0887-6924
CID: 3695832

Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease

Dignan, F; Gujral, D; Ethell, M; Evans, S; Treleaven, J; Morgan, G; Potter, M
Veno-occlusive disease (VOD) is a common and high-risk complication of allogeneic stem cell transplantation (SCT). Defibrotide has recently been used successfully to treat the disorder. We report on 58 patients who received defibrotide prophylaxis without concurrent heparin. No patients fulfilled the Baltimore criteria for VOD or died of the condition within 100 days of SCT. None of this group developed haemorrhagic complications secondary to defibrotide. These observations suggest that prophylaxis with defibrotide alone may reduce the incidence of VOD post-SCT although a randomised controlled trial is warranted to further evaluate its role.
PMID: 17502897
ISSN: 0268-3369
CID: 3695822

Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma

Gahrton, Gösta; Iacobelli, Simona; Bandini, Giuseppe; Björkstrand, Bo; Corradini, Paolo; Crawley, Charles; Hegenbart, Ute; Morgan, Gareth; Kröger, Nicolaus; Schattenberg, Anton; Schönland, Stefan O; Verdonck, Leo F; Volin, Lisa; de Witte, Theo; Niederwieser, Dietger
BACKGROUND AND OBJECTIVES/OBJECTIVE:Peripheral blood stem cells (PBSC) following reduced intensity conditioning (RIC) are being increasingly used for allogeneic transplantation in multiple myeloma. The purpose of this study was to compare outcome of patients transplanted with either PBSC or bone marrow (BM) following RIC or myeloablative conditioning (MAC). DESIGN AND METHODS/METHODS:Data from 1,667 patients who had received an allogeneic identical sibling donor transplant for multiple myeloma from 1994 to 2003 were analyzed. Comparisons were made between results of PBSC and BM transplants after conditioning with RIC or MAC. RESULTS:The engraftment rate was faster with PBSC than with BM (median: 14 and 18 days for neutrophils and 15 and 25 days for platelets respectively) irrespectively of whether RIC or MAC was used. The incidence of acute graft-versus-host disease (GVHD) did not differ significantly between the groups while chronic GVHD was more prevalent in PBSC recipients irrespectively of whether they had RIC or MAC. Non-relapse mortality did not differ between PBSC and BM recipients, but was significantly higher in those treated with MAC than in those given RIC irrespectively of the cell source. The relapse/progression rate did not differ between PBSC and BM recipients, but was significantly higher in those given RIC, irrespectively of the cell source. There was no significant difference in overall or progression-free survival between patients given PBSC or BM transplants. INTERPRETATION AND CONCLUSIONS/CONCLUSIONS:Although transplantation of PBSC is associated with faster engraftment and more frequent chronic GVHD, overall survival, non-relapse mortality, relapse/progression and progression-free survival are similar to those following BM transplants. However both PBSC and BM transplants are associated with lower non-relapse mortality, lower response rate and higher relapse/progression if RIC is used instead of MAC.
PMID: 18024400
ISSN: 1592-8721
CID: 3695852

Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: a double-blind randomized, placebo-controlled study

Sirohi, B; Powles, R; Morgan, G; Treleaven, J; Kulkarni, S; Horton, C; Saso, R; Rolfe, D; Cook, G; Shaw, C; Wass, J
In vivo and in vitro studies suggest human growth hormone (hGH) receptors on bone marrow stem cells may be biologically active and could be exploited to promote haemopoetic recovery after intensive chemotherapy. Patients with haematological malignancies receiving intensive chemotherapy and requiring hospitalization were randomized in a double-blind, placebo-controlled single-centre trial. Patients were randomly assigned to receive either hGH 500 microg/day or placebo, for 6 weeks. There was no significant difference in patient characteristics at baseline between the placebo and treatment arms. Patients treated with hGH showed significantly faster recovery of platelets to 25 x 10(9)/l (median of 16 versus 19 days; P = 0.03) compared to the placebo-controlled arm (hazard ratio 1.47 favouring hGH, 95% confidence interval (CI), 1.03-2.08). Time to relapse did not differ significantly between arms. There was no change in the anthropometric parameters at the start and end of hGH/placebo therapy. The study drug was well tolerated. Treatment with hGH in physiological doses improves platelet recovery, but is not associated with a lower relapse rate or improved anthropometric parameters in patients receiving intensive chemotherapy.
PMID: 17143302
ISSN: 0268-3369
CID: 3695802

An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-alpha2b in patients with multiple myeloma maintained on a steady dose of interferon-alpha2b

Sirohi, B; Powles, R; Lawrence, D; Treleaven, J; Kulkarni, S; Leary, A; Rudin, C; Horton, C; Morgan, G
PURPOSE/OBJECTIVE:To compare the effects of pegylated interferon-alpha2b (P-IFN) and interferon-alpha2b (IFN) on quality of life (QoL) and toxicity in patients with multiple myeloma maintained on a steady dose of IFN. PATIENTS AND METHODS/METHODS:Consenting, eligible myeloma patients on IFN maintenance therapy for at least 6 weeks were randomly (1:1) allocated to receive P-IFN for 3 months followed by IFN for 3 months, or to continue with IFN for 3 months followed by P-IFN for 3 months (cross-over design). Patients were assessed for toxicity and QoL. Dose of P-IFN was equivalent to IFN. RESULTS:The study enrolled 60 patients. At enrollment, 35 patients were in complete remission, 20 in partial remission and 5 were minimal responders. P-IFN was associated with significantly better global QoL score (mean difference 8.4; P = 0.0002). There was a significant improvement in functional scales--physical (P = 0.03), emotional (P = 0.04), social (P = 0.0008) with P-IFN. Fatigue (P = 0.0003), pain (P = 0.02) and appetite loss (P = 0.003) symptom scales were less in patients while on P-IFN. There were no statistically significant differences between treatment arms in QoL as measured by QLQ-MY24. CONCLUSION/CONCLUSIONS:These data suggest that patients on P-IFN have a better QoL. Dose escalation studies are warranted to investigate potential impact on survival.
PMID: 17693652
ISSN: 0923-7534
CID: 3695842